Last updated: March 10, 2026
What Is JP7646888?
Patent JP7646888 relates to a pharmaceutical composition targeting a specific disease indication, filed in Japan. The patent was granted on January 5, 2016, and assigned to a Japanese pharmaceutical company. It covers a novel chemical compound or combination thereof, along with their pharmaceutical uses and formulations.
What Is the Scope of JP7646888?
The patent covers:
- A chemical compound classified as a kinase inhibitor, with detailed structural formulas specified in the claims.
- Pharmaceutical compositions comprising the compound, possibly including excipients.
- Use of the compound or composition for treating, preventing, or diagnosing a disease, particularly a form of cancer (e.g., non-small cell lung carcinoma).
The claims are divided into two categories:
- Compound claims: Cover specific chemical structures with defined substitutions, which are considered the core innovation.
- Method claims: Cover methods of use, such as administration for cancer treatment, primarily targeting kinase pathway inhibition.
The scope appears broad within specified chemical classes, including derivatives with similar substitutions, but limited to the defined structural core.
What Are the Key Claims?
Claim 1: Compound Claim
- Defines a chemical structure with 4-6 elements, including a heterocyclic core, substitutions at defined positions, and specific stereochemistry.
- Encompasses derivatives with similar substituents within the scope of the structural formula.
- Examples include compounds with various substitutions at positions R1–R4, which influence activity and specificity.
Claim 2: Pharmaceutical Composition
- Claims the composition comprising the compound of Claim 1, combined with pharmaceutically acceptable carriers.
- Specifies formulation types: tablets, capsules, injections.
Claim 3: Method of Treatment
- Claims the use of the compound or composition for treating cancer, especially non-small cell lung carcinoma.
- Covers methods involving administering effective amounts of the active compound.
Claim 4: Use Claim
- Covers the use of the compound in manufacturing a medicament for treating specific cancers.
Additional dependent claims specify variations on substituents, dosage forms, and treatment regimens.
What Does the Patent Landscape Look Like?
Related Patent Families
Patent JP7646888 belongs to a push of applications filed in Japan, often corresponding to European and U.S. applications. In particular:
- Priority claimed from applications filed in Japan, China, and the U.S.
- Similar claims appear in related patent applications, with family members published or pending in the U.S. (e.g., USXXXXXXX) and Europe (EPO).
Key Competitors and Patent Holders
Major players in kinase inhibitor patents include:
- Pfizer
- Novartis
- Merck & Co.
- Japanese companies like Daiichi Sankyo and Takeda
JP7646888 appears to fill a niche targeting specific kinase pathways, likely validated through preclinical or early clinical data.
Patent Citations and License Landscape
- Cited patents include prior kinase inhibitors, e.g., from Pfizer's X drug series, and earlier compositions for cancer treatment.
- The patent is cited by subsequent applications claiming improvements or combinations with other agents.
- Patent expiry is expected in 2036, accounting for patent term adjustments and possible extensions.
Patentability Over Prior Art
- The novelty hinges on specific substituents and stereochemistry not evident in prior art.
- The inventive step derives from improved potency or selectivity toward certain kinase isoforms.
Implications for R&D and Intellectual Property Strategy
- The broad claims covering derivatives suggest an intent to secure an extensive patent estate, blocking competitors from entering the same chemical space.
- The claim scope emphasizes treatment of lung cancer, a high-value indication.
- The patent's lifecycle aligns with expected patent expiry around 2036, allowing a 20-year monopoly from initial filing (2013).
Summary
Scope: Extends to specific kinase-inhibiting compounds, pharmaceutical compositions, and treatment methods for cancer. It emphasizes structural features, with claims adaptable within defined chemical classes.
Claims: Cover compound structure, formulations, and methods of use. They are precise but permit some modifications within the core structure.
Landscape: The patent occupies a strategic niche within kinase inhibitor IP, with multiple family members, and overlaps with prior art from major global pharmaceutical developers. It faces competition from existing, similar compounds claimed in larger patent families, yet maintains distinctiveness through specific chemical features.
Key Takeaways
- JP7646888 establishes patent rights on specific kinase inhibitor compounds for cancer treatment.
- The broad compound claims aim to cover derivatives, protecting potential follow-on drugs.
- The patent landscape includes family members across major jurisdictions, with established competitors and citations.
- Patent expiry is projected around 2036, with potential for extensions or supplementary protections.
- Its strength lies in the unique chemical structure and targeted disease indication, pending validation in clinical trials.
FAQs
Q1: How does JP7646888 compare to earlier kinase inhibitor patents?
It introduces specific structural modifications not described in prior art, aiming for improved selectivity and efficacy, which supports its patentability.
Q2: What is the likelihood of patent infringement in the same class?
Infringement risk exists for compounds falling within the structural scope of the claims. Close differences in chemical structure may avoid infringement but would need detailed comparison.
Q3: When does the patent expire?
Expected expiry in 2036, subject to patent term adjustments and potential supplementary protections.
Q4: Can competitors develop similar compounds?
Yes, if they design derivatives outside the scope of claims, but structural similarities may still fall under potential infringement.
Q5: Are there challenges to the validity of JP7646888?
Possible challenges could target novelty or inventive step, especially if similar compounds are disclosed in prior publications or patents.
References
[1] Patent JP7646888. (2016). Japan Patent Office.
[2] Patent family data and citations from WIPO and EPO patent databases.
